Latozinemab
- Generic Name
- Latozinemab
- Drug Type
- Biotech
- Unique Ingredient Identifier
- IKT0XSS2XB
A Study to Investigate Lithium Brain/Plasma Pharmacokinetics and Safety of an AL001 Oral Capsule Compared to a Marketed Immediate-release Lithium Carbonate Capsule in Healthy Adult Subjects
- Conditions
- PharmacokineticsNeurology
- Interventions
- First Posted Date
- 2025-04-10
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Alzamend Neuro, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT06921590
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD
- Conditions
- Wet Age-related Macular Degeneration (wAMD)
- Interventions
- First Posted Date
- 2025-02-21
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06839339
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Hospital, Beijing, China
Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD
- Conditions
- Wet Age-related Macular Degeneration (wAMD)
- Interventions
- First Posted Date
- 2024-11-27
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Beijing Anlong Biopharmaceutical Co., Ltd.
- Target Recruit Count
- 21
- Registration Number
- NCT06707753
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Hospital, Beijing, China
Continuation Study for Latozinemab
- First Posted Date
- 2023-11-01
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT06111014
- Locations
- 🇵🇹
Centro Hospitalar E Universitario de Coimbra EPE, Coimbra, Portugal
🇺🇸Dignity Health - Arizona, Phoenix, Arizona, United States
🇺🇸Mayo Comprehensive Cancer Center - PPDS, Rochester, Minnesota, United States
Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
- Conditions
- Alzheimer's DiseaseHealthy Non-elderly and Elderly Adults
- Interventions
- Other: Placebo
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Alzamend Neuro, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05363293
- Locations
- 🇨🇦
Altasciences, Mount-Royal, Quebec, Canada
🇺🇸CenExel iResearch, LLC, Decatur, Georgia, United States
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
- First Posted Date
- 2021-09-22
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT05053035
- Locations
- 🇺🇸
University of South Florida, Tampa, Florida, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University School of Medicine, Saint Louis, Missouri, United States
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
- Conditions
- Frontotemporal Dementia
- Interventions
- First Posted Date
- 2020-05-05
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT04374136
- Locations
- 🇮🇹
IRCCS - Centro S. Giovanni di Dio Fatebenefratelli, Brescia, Italy
🇮🇹Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milano, Italy
🇮🇹Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta, Milano, Italy
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
- First Posted Date
- 2019-06-17
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Alector Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03987295
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇳🇱Erasmus University Medical Center, Rotterdam, Netherlands
🇬🇧University College London, London, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.